{
 "disease": "waldenstrom-macroglobulinemia",
 "label": "Waldenstr\u00f6m macroglobulinaemia",
 "url": "https://usebiotransfer.org/disease/waldenstrom-macroglobulinemia/",
 "built": "2026-09-17",
 "facts_hash": {
  "answers": "9ba516b7a335",
  "targets": "b0987a02e620"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-17",
  "trials": "2026-09-17"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "MYD88",
   "ensembl": "ENSG00000172936",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "CXCR4",
   "ensembl": "ENSG00000121966",
   "n_drug_entries": 8,
   "n_distinct_drugs": 8,
   "drugs": {
    "BALIXAFORTIDE": "PHASE_3",
    "BURIXAFOR": "PHASE_2",
    "CTCE-9908": "PHASE_1_2",
    "MAVORIXAFOR": "APPROVAL",
    "MOTIXAFORTIDE": "APPROVAL",
    "MSX-122": "PHASE_1",
    "PLERIXAFOR": "APPROVAL",
    "ULOCUPLUMAB": "PHASE_3"
   },
   "approved": [
    "MAVORIXAFOR",
    "MOTIXAFORTIDE",
    "PLERIXAFOR"
   ],
   "n_approved": 3,
   "approved_for": {
    "MAVORIXAFOR": [
     "inborn error of immunity"
    ],
    "MOTIXAFORTIDE": [
     "plasma cell myeloma"
    ],
    "PLERIXAFOR": [
     "acute lymphoblastic leukemia",
     "plasma cell myeloma",
     "non-Hodgkin lymphoma",
     "lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "BTK",
   "ensembl": "ENSG00000010671",
   "n_drug_entries": 24,
   "n_distinct_drugs": 20,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "ACALABRUTINIB": "APPROVAL",
    "BMS-986142": "PHASE_2",
    "BRANEBRUTINIB": "PHASE_2",
    "EDRALBRUTINIB": "PHASE_2",
    "ELSUBRUTINIB": "PHASE_2",
    "EVOBRUTINIB": "PHASE_3",
    "FENEBRUTINIB": "PHASE_3",
    "IBRUTINIB": "APPROVAL",
    "MSC-2364447": "PHASE_1",
    "ORELABRUTINIB": "APPROVAL",
    "PIRTOBRUTINIB": "APPROVAL",
    "POSELTINIB": "PHASE_2",
    "RILZABRUTINIB": "APPROVAL",
    "RITLECITINIB": "APPROVAL",
    "SPEBRUTINIB": "PHASE_2",
    "TIRABRUTINIB": "APPROVAL",
    "TOLEBRUTINIB": "PREAPPROVAL",
    "VECABRUTINIB": "PHASE_1_2",
    "ZANUBRUTINIB": "APPROVAL"
   },
   "approved": [
    "ACALABRUTINIB",
    "IBRUTINIB",
    "ORELABRUTINIB",
    "PIRTOBRUTINIB",
    "RILZABRUTINIB",
    "RITLECITINIB",
    "TIRABRUTINIB",
    "ZANUBRUTINIB"
   ],
   "n_approved": 8,
   "approved_for": {
    "ACALABRUTINIB": [
     "B-cell chronic lymphocytic leukemia",
     "childhood leukemia",
     "mantle cell lymphoma"
    ],
    "IBRUTINIB": [
     "macroglobulinemia",
     "mantle cell lymphoma",
     "B-cell chronic lymphocytic leukemia"
    ],
    "ORELABRUTINIB": [],
    "PIRTOBRUTINIB": [
     "mantle cell lymphoma",
     "non-Hodgkin lymphoma"
    ],
    "RILZABRUTINIB": [
     "autoimmune thrombocytopenic purpura"
    ],
    "RITLECITINIB": [
     "alopecia areata"
    ],
    "TIRABRUTINIB": [],
    "ZANUBRUTINIB": [
     "mantle cell lymphoma",
     "B-cell chronic lymphocytic leukemia",
     "lymphoplasmacytic lymphoma",
     "Waldenstrom macroglobulinemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "ARID1A",
   "ensembl": "ENSG00000117713",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "CD79B",
   "ensembl": "ENSG00000007312",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "POLATUZUMAB VEDOTIN": "APPROVAL"
   },
   "approved": [
    "POLATUZUMAB VEDOTIN"
   ],
   "n_approved": 1,
   "approved_for": {
    "POLATUZUMAB VEDOTIN": [
     "diffuse large B-cell lymphoma",
     "B-cell non-Hodgkin lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "BCL2",
   "ensembl": "ENSG00000171791",
   "n_drug_entries": 7,
   "n_distinct_drugs": 5,
   "drugs": {
    "APG-2575": "PHASE_3",
    "NAVITOCLAX": "APPROVAL",
    "OBATOCLAX": "PHASE_3",
    "OBLIMERSEN": "APPROVAL",
    "VENETOCLAX": "APPROVAL"
   },
   "approved": [
    "NAVITOCLAX",
    "OBLIMERSEN",
    "VENETOCLAX"
   ],
   "n_approved": 3,
   "approved_for": {
    "NAVITOCLAX": [],
    "OBLIMERSEN": [],
    "VENETOCLAX": [
     "B-cell chronic lymphocytic leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CD19",
   "ensembl": "ENSG00000177455",
   "n_drug_entries": 14,
   "n_distinct_drugs": 14,
   "drugs": {
    "AXICABTAGENE CILOLEUCEL": "APPROVAL",
    "BLINATUMOMAB": "APPROVAL",
    "BREXUCABTAGENE AUTOLEUCEL": "APPROVAL",
    "COLTUXIMAB RAVTANSINE": "PHASE_2",
    "DENINTUZUMAB MAFODOTIN": "PHASE_2",
    "INEBILIZUMAB": "APPROVAL",
    "LISOCABTAGENE MARALEUCEL": "APPROVAL",
    "LONCASTUXIMAB TESIRINE": "APPROVAL",
    "MDX-1342": "PHASE_2",
    "OBECABTAGENE AUTOLEUCEL": "APPROVAL",
    "OBEXELIMAB": "PHASE_3",
    "ONCOLYSIN B": "PHASE_2",
    "TAFASITAMAB": "APPROVAL",
    "TISAGENLECLEUCEL": "APPROVAL"
   },
   "approved": [
    "AXICABTAGENE CILOLEUCEL",
    "BLINATUMOMAB",
    "BREXUCABTAGENE AUTOLEUCEL",
    "INEBILIZUMAB",
    "LISOCABTAGENE MARALEUCEL",
    "LONCASTUXIMAB TESIRINE",
    "OBECABTAGENE AUTOLEUCEL",
    "TAFASITAMAB",
    "TISAGENLECLEUCEL"
   ],
   "n_approved": 9,
   "approved_for": {
    "AXICABTAGENE CILOLEUCEL": [
     "diffuse large B-cell lymphoma",
     "follicular lymphoma"
    ],
    "BLINATUMOMAB": [
     "acute lymphoblastic leukemia",
     "B-cell acute lymphoblastic leukemia",
     "lymphoid leukemia"
    ],
    "BREXUCABTAGENE AUTOLEUCEL": [
     "mantle cell lymphoma"
    ],
    "INEBILIZUMAB": [
     "neuromyelitis optica"
    ],
    "LISOCABTAGENE MARALEUCEL": [
     "diffuse large B-cell lymphoma",
     "follicular lymphoma",
     "neoplasm of mediastinum"
    ],
    "LONCASTUXIMAB TESIRINE": [
     "diffuse large B-cell lymphoma",
     "B-cell neoplasm",
     "B-cell non-Hodgkin lymphoma"
    ],
    "OBECABTAGENE AUTOLEUCEL": [
     "B-cell acute lymphoblastic leukemia"
    ],
    "TAFASITAMAB": [
     "diffuse large B-cell lymphoma",
     "lymphoma"
    ],
    "TISAGENLECLEUCEL": [
     "diffuse large B-cell lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "MS4A1",
   "ensembl": "ENSG00000156738",
   "n_drug_entries": 18,
   "n_distinct_drugs": 18,
   "drugs": {
    "EPCORITAMAB": "APPROVAL",
    "FBT-A05": "PHASE_1_2",
    "GLOFITAMAB": "APPROVAL",
    "LFB-R603": "PHASE_1",
    "MOSUNETUZUMAB": "APPROVAL",
    "MT-3724": "PHASE_2",
    "OBINUTUZUMAB": "APPROVAL",
    "OCARATUZUMAB": "PHASE_2",
    "OCRELIZUMAB": "APPROVAL",
    "ODRONEXTAMAB": "APPROVAL",
    "OFATUMUMAB": "APPROVAL",
    "RITUXIMAB": "APPROVAL",
    "TOSITUMOMAB": "APPROVAL",
    "TOSITUMOMAB 131I": "PHASE_3",
    "TRU-015": "PHASE_2",
    "UBLITUXIMAB": "APPROVAL",
    "VELTUZUMAB": "PHASE_2",
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": "APPROVAL"
   },
   "approved": [
    "EPCORITAMAB",
    "GLOFITAMAB",
    "MOSUNETUZUMAB",
    "OBINUTUZUMAB",
    "OCRELIZUMAB",
    "ODRONEXTAMAB",
    "OFATUMUMAB",
    "RITUXIMAB",
    "TOSITUMOMAB",
    "UBLITUXIMAB",
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN"
   ],
   "n_approved": 11,
   "approved_for": {
    "EPCORITAMAB": [
     "follicular lymphoma",
     "B-cell non-Hodgkin lymphoma",
     "diffuse large B-cell lymphoma"
    ],
    "GLOFITAMAB": [
     "diffuse large B-cell lymphoma"
    ],
    "MOSUNETUZUMAB": [
     "follicular lymphoma"
    ],
    "OBINUTUZUMAB": [
     "follicular lymphoma",
     "B-cell chronic lymphocytic leukemia"
    ],
    "OCRELIZUMAB": [
     "multiple sclerosis",
     "diffuse large B-cell lymphoma",
     "relapsing-remitting multiple sclerosis",
     "chronic progressive multiple sclerosis"
    ],
    "ODRONEXTAMAB": [
     "follicular lymphoma"
    ],
    "OFATUMUMAB": [
     "relapsing-remitting multiple sclerosis",
     "B-cell chronic lymphocytic leukemia",
     "multiple sclerosis",
     "secondary progressive multiple sclerosis"
    ],
    "RITUXIMAB": [
     "non-Hodgkin lymphoma",
     "granulomatosis with polyangiitis",
     "B-cell chronic lymphocytic leukemia",
     "acute lymphoblastic leukemia",
     "rheumatoid arthritis",
     "microscopic polyangiitis",
     "pemphigus",
     "vasculitis"
    ],
    "TOSITUMOMAB": [
     "non-Hodgkin lymphoma"
    ],
    "UBLITUXIMAB": [
     "multiple sclerosis",
     "relapsing-remitting multiple sclerosis",
     "chronic progressive multiple sclerosis"
    ],
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": [
     "follicular lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "IRAK4",
   "ensembl": "ENSG00000198001",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "ZIMLOVISERTIB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "HCK",
   "ensembl": "ENSG00000101336",
   "n_drug_entries": 6,
   "n_distinct_drugs": 6,
   "drugs": {
    "BOSUTINIB": "APPROVAL",
    "DASATINIB": "APPROVAL",
    "ENMD-981693": "PHASE_2",
    "ILORASERTIB": "PHASE_2",
    "TG100-801": "PHASE_2",
    "XL-228": "PHASE_1"
   },
   "approved": [
    "BOSUTINIB",
    "DASATINIB"
   ],
   "n_approved": 2,
   "approved_for": {
    "BOSUTINIB": [
     "breast cancer"
    ],
    "DASATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "acute lymphoblastic leukemia",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KMT2D",
   "ensembl": "ENSG00000167548",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "BTK": {
    "n": 14,
    "n_observational": 0,
    "n_active": 8,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06708897",
      "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955499",
      "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02332980",
      "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02950220",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03037645",
      "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03479268",
      "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03679624",
      "title": "Daratumumab Plus Ibrutinib in Patients With Waldenstr\u04e7m's Macroglobulinemia",
      "status": "TERMINATED",
      "last_update": "2023-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522284",
      "title": "PRECISE CURATE.AI Pilot Clinical Trial",
      "status": "UNKNOWN",
      "last_update": "2023-03-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176691",
      "title": "HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL",
      "status": "WITHDRAWN",
      "last_update": "2023-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05734495",
      "title": "Pirtobrutinib and Venetoclax in Waldenstr\u00f6m Macroglobulinemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07592481",
      "title": "Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BTK",
     "ibrutinib",
     "Imbruvica",
     "zanubrutinib",
     "Brukinsa",
     "acalabrutinib",
     "pirtobrutinib",
     "tirabrutinib"
    ]
   },
   "CD20": {
    "n": 22,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020800",
      "title": "Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060294",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia",
      "status": "TERMINATED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00142116",
      "title": "Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2014-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496873",
      "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",
      "status": "COMPLETED",
      "last_update": "2023-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536978",
      "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00546793",
      "title": "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL",
      "status": "COMPLETED",
      "last_update": "2021-08-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00801281",
      "title": "First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.",
      "status": "COMPLETED",
      "last_update": "2017-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01282424",
      "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2019-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732913",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732926",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02339922",
      "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02371148",
      "title": "Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's",
      "status": "COMPLETED",
      "last_update": "2020-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02384954",
      "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab",
      "status": "TERMINATED",
      "last_update": "2024-07-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02924402",
      "title": "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03010358",
      "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "status": "COMPLETED",
      "last_update": "2022-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277729",
      "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799275",
      "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT03019666",
       "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
       "status": "COMPLETED",
       "last_update": "2022-11-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03277729",
       "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD20",
     "rituximab",
     "obinutuzumab",
     "ofatumumab"
    ]
   },
   "BCL-2": {
    "n": 6,
    "n_observational": 1,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06708897",
      "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799275",
      "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05734495",
      "title": "Pirtobrutinib and Venetoclax in Waldenstr\u00f6m Macroglobulinemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387471",
      "title": "Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenstr\u00f6m Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BCL-2",
     "BCL2",
     "venetoclax",
     "sonrotoclax"
    ]
   },
   "CXCR4": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CXCR4",
     "mavorixafor",
     "ulocuplumab",
     "plerixafor"
    ]
   },
   "proteasome": {
    "n": 6,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00142129",
      "title": "Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2011-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00837174",
      "title": "Relapsed and/or Refractory Non-Hodgkin Lymphoma Study",
      "status": "WITHDRAWN",
      "last_update": "2017-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02142530",
      "title": "Carfilzomib Plus Belinostat in Relapsed/Refractory NHL",
      "status": "COMPLETED",
      "last_update": "2018-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02339922",
      "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02371148",
      "title": "Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's",
      "status": "COMPLETED",
      "last_update": "2020-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03335098",
      "title": "Study of VTD in Waldenstrom's Macroglobulinemia",
      "status": "UNKNOWN",
      "last_update": "2017-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "bortezomib",
     "carfilzomib",
     "ixazomib"
    ]
   },
   "CD19": {
    "n": 8,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04545762",
      "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05281809",
      "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06340737",
      "title": "AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805375",
      "title": "A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2018-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02153580",
      "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277729",
      "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04450069",
      "title": "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04488354",
      "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 6,
     "n_observational": 0,
     "n_active": 5,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04545762",
       "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05281809",
       "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2025-01-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06340737",
       "title": "AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas",
       "status": "RECRUITING",
       "last_update": "2026-08-12",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02153580",
       "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03277729",
       "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04488354",
       "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
       "status": "COMPLETED",
       "last_update": "2026-04-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD19",
     "CD19 CAR",
     "CAR-T"
    ]
   },
   "IRAK4": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "IRAK4",
     "emavusertib",
     "CA-4948"
    ]
   },
   "HCK": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "HCK",
     "KIN-8194"
    ]
   },
   "BTK degrader": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BTK degrader",
     "NX-5948",
     "BGB-16673"
    ]
   },
   "bendamustine": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01732926",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02153580",
      "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02371148",
      "title": "Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's",
      "status": "COMPLETED",
      "last_update": "2020-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02153580",
       "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "bendamustine"
    ]
   }
  },
  "by_drug": {
   "ACALABRUTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IBRUTINIB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955499",
      "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02332980",
      "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02950220",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03479268",
      "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03679624",
      "title": "Daratumumab Plus Ibrutinib in Patients With Waldenstr\u04e7m's Macroglobulinemia",
      "status": "TERMINATED",
      "last_update": "2023-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522284",
      "title": "PRECISE CURATE.AI Pilot Clinical Trial",
      "status": "UNKNOWN",
      "last_update": "2023-03-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LFB-R603": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04635683",
      "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBINUTUZUMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03010358",
      "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PIRTOBRUTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05734495",
      "title": "Pirtobrutinib and Venetoclax in Waldenstr\u00f6m Macroglobulinemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RITUXIMAB": {
    "n": 16,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020800",
      "title": "Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060294",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia",
      "status": "TERMINATED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00142116",
      "title": "Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2014-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496873",
      "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",
      "status": "COMPLETED",
      "last_update": "2023-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536978",
      "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00801281",
      "title": "First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.",
      "status": "COMPLETED",
      "last_update": "2017-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01282424",
      "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2019-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732913",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732926",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02339922",
      "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02371148",
      "title": "Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's",
      "status": "COMPLETED",
      "last_update": "2020-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02384954",
      "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab",
      "status": "TERMINATED",
      "last_update": "2024-07-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "status": "COMPLETED",
      "last_update": "2022-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799275",
      "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "UBLITUXIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04635683",
      "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VECABRUTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03037645",
      "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VELTUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00546793",
      "title": "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL",
      "status": "COMPLETED",
      "last_update": "2021-08-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VENETOCLAX": {
    "n": 5,
    "n_observational": 1,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06708897",
      "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05734495",
      "title": "Pirtobrutinib and Venetoclax in Waldenstr\u00f6m Macroglobulinemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387471",
      "title": "Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenstr\u00f6m Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00060294",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia",
      "status": "TERMINATED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZANUBRUTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}